Carma Fund

Akribion Genomics develops gene-editing tools and cancer therapies using CRISPR nuclease technology.

Founded in 2018, Aignostics develops AI-powered diagnostics and pathology software solutions for pharmaceutical research and clinical applications. Its explainable AI overcomes the limitations of conventional 'black-box' AI by providing precise heatmaps and image overlays, enabling pathologists to verify results quickly.

Symphera is a developer of an innovative surgical system focused on enhancing the efficiency of minimally invasive procedures. The company specializes in a laparoscopic surgical tool that aims to radically simplify and expedite surgical processes. By prioritizing control, autonomy, safety, and efficiency, Symphera enables healthcare providers to perform surgeries with greater precision and effectiveness. Through its all-in-one surgical system, the company is committed to transforming the landscape of surgical practices, making advanced medical techniques more accessible and streamlined for both practitioners and patients.

Thryve develops a platform that enables access to fragmented wearable device and medical data silos through a single integration. It unifies users' health data from various sources like smartwatches, blood glucose meters, and popular apps such as Apple Health and Google Fit, providing a continuous stream of harmonized health information for care providers.

Allogenetics develops transplantation technology to address organ rejection by treating the transplant itself rather than suppressing the patient's immune system, with the goal of improving graft survival and patient outcomes. By focusing on the graft, the company aims to increase the success rate of organ transplantation and enhance quality of life for recipients.

Acorai develops a non-invasive heart failure monitoring platform centered around direct intracardiac pressure monitoring. Its patented technology combines sensor technologies and machine learning to enable accurate, cost-efficient care, reducing re-hospitalization and mortality rates.

InContAlert is a deep tech company innovating in the field of incontinence management. It develops an mHealth device that monitors urinary bladder filling levels using advanced algorithms. The device sends alerts to users and caregivers when predefined thresholds are reached, minimizing risks associated with uncontrolled urine loss or bladder distension.